Andrea Anichini

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 74 publications

Transposable elements and homotypic niches drive immune dynamics and resistance in melanoma epigenetic-based immunotherapy.

Transposable elements and homotypic niches drive immune dynamics and resistance in melanoma epigenetic-based immunotherapy.

Journal: Science advances

Published: August 07, 2026

Mucosal Melanoma of the Head and Neck: A 45-Year Experience of a Tertiary Cancer Center.

Mucosal Melanoma of the Head and Neck: A 45-Year Experience of a Tertiary Cancer Center.

Journal: Cancers

Published: March 17, 2026

Transposable Elements and Homotypic Niches Drive Immune Dynamics and Resistance in Melanoma Epigenetic-based immunotherapy.

Transposable Elements and Homotypic Niches Drive Immune Dynamics and Resistance in Melanoma Epigenetic-based immunotherapy.

Journal: bioRxiv : the preprint server for biology

Published: November 24, 2025

Circulating EV-microRNAs are dynamic biomarkers of resistance to therapeutic immunomodulation in metastatic melanoma.

Circulating EV-microRNAs are dynamic biomarkers of resistance to therapeutic immunomodulation in metastatic melanoma.

Journal: Communications medicine

Published: August 19, 2025

Integrated multi-omics profiling reveals the role of the DNA methylation landscape in shaping biological heterogeneity and clinical behaviour of metastatic melanoma.

Integrated multi-omics profiling reveals the role of the DNA methylation landscape in shaping biological heterogeneity and clinical behaviour of metastatic melanoma.

Journal: Journal of experimental & clinical cancer research : CR

Published: April 01, 2025

DNA methylation status classifies pleural mesothelioma cells according to their immune profile: implication for precision epigenetic therapy.

DNA methylation status classifies pleural mesothelioma cells according to their immune profile: implication for precision epigenetic therapy.

Journal: Journal of experimental & clinical cancer research : CR

Published: December 24, 2024

Tumor DNA methylation subtypes predict immunotherapy outcomes in pleural mesothelioma patients in the NIBIT-EPI-MESO study.

Tumor DNA methylation subtypes predict immunotherapy outcomes in pleural mesothelioma patients in the NIBIT-EPI-MESO study.

Journal: Nature genetics

Published: September 10, 2024

Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches.

Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches.

Journal: Journal of translational medicine

Published: December 22, 2023

Antibody dependent cellular cytotoxicity-inducing anti-EGFR antibodies as effective therapeutic option for cutaneous melanoma resistant to BRAF inhibitors.

Antibody dependent cellular cytotoxicity-inducing anti-EGFR antibodies as effective therapeutic option for cutaneous melanoma resistant to BRAF inhibitors.

Journal: Frontiers in immunology

Published: November 10, 2023

Gut Microbiota, Metabolome, and Body Composition Signatures of Response to Therapy in Patients with Advanced Melanoma.

Gut Microbiota, Metabolome, and Body Composition Signatures of Response to Therapy in Patients with Advanced Melanoma.

Journal: International journal of molecular sciences

Published: May 23, 2023

PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis.

PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis.

Journal: Journal for immunotherapy of cancer

Published: April 09, 2023

Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial.

Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial.

Journal: Nature communications

Published: December 22, 2022

Showing 1-12 of 74

Last Updated: 09/26/2026